UPDATE 1-U.S. FDA to review Mylan's generic Copaxone Mon Sep 14, 2009 7:38am EDT
Teva shares fall 3.8 percent in U.S.
Momenta Pharmaceuticals Inc (MNTA.O) said in July 2008 that the U.S. Food and Drug Administration had accepted its generic Copaxone application for review. Teva sued Momenta and partner Novartis AG (NOVN.VX) the following month for patent infringement.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.